A Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome
Status:
Withdrawn
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine the response rate according to the
International Working Group Response criteria for the combination of FF-10501-01 and
azacitidine in patients previously untreated with hypomethylating agents, with Int2/High risk
MDS according to the IPSS, and Intermediate/High/Very-High risk MDS according to the IPSS-R,
or who are otherwise candidates for treatment with azacitidine.